A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.

8q24 African ancestry Familial prostate cancer Family history Genetic variant Genetics Health disparities Prostate cancer

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
09 2020
Historique:
received: 24 01 2020
accepted: 23 04 2020
pubmed: 16 5 2020
medline: 16 7 2021
entrez: 16 5 2020
Statut: ppublish

Résumé

Although men of African ancestry have a high risk of prostate cancer (PCa), no genes or mutations have been identified that contribute to familial clustering of PCa in this population. We investigated whether the African ancestry-specific PCa risk variant at 8q24, rs72725854, is enriched in men with a PCa family history in 9052 cases, 143 cases from high-risk families, and 8595 controls of African ancestry. We found the risk allele to be significantly associated with earlier age at diagnosis, more aggressive disease, and enriched in men with a PCa family history (32% of high-risk familial cases carried the variant vs 23% of cases without a family history and 12% of controls). For cases with two or more first-degree relatives with PCa who had at least one family member diagnosed at age <60 yr, the odds ratios for TA heterozygotes and TT homozygotes were 3.92 (95% confidence interval [CI] = 2.13-7.22) and 33.41 (95% CI = 10.86-102.84), respectively. Among men with a PCa family history, the absolute risk by age 60 yr reached 21% (95% CI = 17-25%) for TA heterozygotes and 38% (95% CI = 13-65%) for TT homozygotes. We estimate that in men of African ancestry, rs72725854 accounts for 32% of the total familial risk explained by all known PCa risk variants. PATIENT SUMMARY: We found that rs72725854, an African ancestry-specific risk variant, is more common in men with a family history of prostate cancer and in those diagnosed with prostate cancer at younger ages. Men of African ancestry may benefit from the knowledge of their carrier status for this genetic risk variant to guide decisions about prostate cancer screening.

Identifiants

pubmed: 32409115
pii: S0302-2838(20)30328-6
doi: 10.1016/j.eururo.2020.04.060
pmc: PMC7805560
mid: NIHMS1610142
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

316-320

Subventions

Organisme : NCI NIH HHS
ID : U10 CA037429
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA165862
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189974
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA214253
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148537
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA196569
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA246063
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES010126
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Références

N Engl J Med. 2012 Jan 12;366(2):141-9
pubmed: 22236224
Nat Genet. 2007 May;39(5):638-44
pubmed: 17401364
Neoplasia. 2014 Nov 20;16(11):900-8
pubmed: 25425964
J Clin Oncol. 2018 Feb 1;36(4):414-424
pubmed: 29236593
Nat Commun. 2018 Nov 5;9(1):4616
pubmed: 30397198
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 29117387
Prostate. 2019 Mar;79(4):333-339
pubmed: 30450585
Epidemiol Rev. 2001;23(1):19-23
pubmed: 11588848
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4173-8
pubmed: 24594601
Hum Genet. 2013 Jan;132(1):5-14
pubmed: 23064873
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73
pubmed: 16945910

Auteurs

Burcu F Darst (BF)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Peggy Wan (P)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Xin Sheng (X)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Jeannette T Bensen (JT)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Sue A Ingles (SA)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Benjamin A Rybicki (BA)

Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.

Barbara Nemesure (B)

Department of Preventive Medicine, Stony Brook University, Stony Brook, NY, USA.

Esther M John (EM)

Department of Epidemiology and Population Health and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

Jay H Fowke (JH)

Division of Epidemiology, Department of Preventive Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA.

Victoria L Stevens (VL)

Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.

Sonja I Berndt (SI)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.

Chad D Huff (CD)

Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Sara S Strom (SS)

Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Jong Y Park (JY)

Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Wei Zheng (W)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, USA.

Elaine A Ostrander (EA)

Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Patrick C Walsh (PC)

The James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, MD, USA.

Shiv Srivastava (S)

Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

John Carpten (J)

Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Thomas A Sellers (TA)

Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Kosj Yamoah (K)

Department of Radiation Oncology and Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Adam B Murphy (AB)

Department of Urology, Northwestern University, Chicago, IL, USA.

Maureen Sanderson (M)

Department of Family and Community Medicine, Meharry Medical College, Nashville, TN, USA.

Dana C Crawford (DC)

Cleveland Institute for Computational Biology, Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.

Susan M Gapstur (SM)

Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.

William S Bush (WS)

Cleveland Institute for Computational Biology, Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.

Melinda C Aldrich (MC)

Department of Thoracic Surgery, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA.

Olivier Cussenot (O)

CeRePP and Sorbonne Universite, GRC n° 5, AP-HP, Tenon Hospital, Paris, France.

Meredith Yeager (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.

Gyorgy Petrovics (G)

Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Jennifer Cullen (J)

Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Christine Neslund-Dudas (C)

Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.

Rick A Kittles (RA)

Department of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Jianfeng Xu (J)

Program for Personalized Cancer Care and Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.

Mariana C Stern (MC)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Zsofia Kote-Jarai (Z)

The Institute of Cancer Research, Sutton, London, UK.

Koveela Govindasami (K)

Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, London, UK.

Anand P Chokkalingam (AP)

School of Public Health, University of California, Berkeley, Berkeley, CA, USA.

Luc Multigner (L)

Inserm U1085-IRSET, Rennes, France.

Marie-Elise Parent (ME)

INRS-Institut Armand-Frappier, Institut National de la Recherche Scientifique, University of Quebec, Laval, Quebec, Canada.

Florence Menegaux (F)

INSERM, Center for Research in Epidemiology and Population Health, Team Cancer-Environment, Université Paris-Saclay, Université Paris-Sud, Villejuif, France.

Geraldine Cancel-Tassin (G)

CeRePP and Sorbonne Universite, GRC n° 5, AP-HP, Tenon Hospital, Paris, France.

Adam S Kibel (AS)

Division of Urology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA; Washington University, St. Louis, MO, USA.

Eric A Klein (EA)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Phyllis J Goodman (PJ)

SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Bettina F Drake (BF)

Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USA.

Jennifer J Hu (JJ)

Sylvester Comprehensive Cancer Center and Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.

Peter E Clark (PE)

Vanderbilt University Medical Center, Nashville, TN, USA.

Pascal Blanchet (P)

Inserm U1085-IRSET, Rennes, France; University Hospital of Pointe-à-Pitre, Guadeloupe, FWI, France; French West Indies University, Pointe-à-Pitre, Guadeloupe, FWI, France.

Graham Casey (G)

Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.

Anselm J M Hennis (AJM)

Department of Preventive Medicine, Stony Brook University, Stony Brook, NY, USA; Chronic Disease Research Centre and Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados.

Alexander Lubwama (A)

School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.

Ian M Thompson (IM)

Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Robin Leach (R)

Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Susan M Gundell (SM)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Loreall Pooler (L)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Lucy Xia (L)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

James L Mohler (JL)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.

Elizabeth T H Fontham (ETH)

School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

Gary J Smith (GJ)

Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA.

Jack A Taylor (JA)

Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA; Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.

Rosalind A Eeles (RA)

The Institute of Cancer Research, Sutton, London, UK; Royal Marsden NHS Foundation Trust, London, UK.

Laurent Brureau (L)

Inserm U1085-IRSET, Rennes, France; University Hospital of Pointe-à-Pitre, Guadeloupe, FWI, France; French West Indies University, Pointe-à-Pitre, Guadeloupe, FWI, France.

Stephen J Chanock (SJ)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.

Stephen Watya (S)

School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda; Uro Care, Kampala, Uganda.

Janet L Stanford (JL)

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.

Diptasri Mandal (D)

Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

William B Isaacs (WB)

The James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, MD, USA.

Kathleen Cooney (K)

Department of Medicine, Duke University of Medicine, Durham, NC, USA.

William J Blot (WJ)

Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, USA.

David V Conti (DV)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Christopher A Haiman (CA)

Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: haiman@usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH